Increased Plasma Heparanase Activity in COVID-19 Patients
Reports suggest a role of endothelial dysfunction and loss of endothelial barrier function in COVID-19. It is well established that the endothelial glycocalyx-degrading enzyme heparanase contributes to vascular leakage and inflammation. Low molecular weight heparins (LMWH) serve as an inhibitor of h...
Main Authors: | Baranca Buijsers, Cansu Yanginlar, Aline de Nooijer, Inge Grondman, Marissa L. Maciej-Hulme, Inge Jonkman, Nico A. F. Janssen, Nils Rother, Mark de Graaf, Peter Pickkers, Matthijs Kox, Leo A. B. Joosten, Tom Nijenhuis, Mihai G. Netea, Luuk Hilbrands, Frank L. van de Veerdonk, Raphaël Duivenvoorden, Quirijn de Mast, Johan van der Vlag |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.575047/full |
Similar Items
-
Heparanase-2 protein and peptides have a protective effect on experimental glomerulonephritis and diabetic nephropathy
by: Baranca Buijsers, et al.
Published: (2023-04-01) -
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
by: Baranca Buijsers, et al.
Published: (2020-09-01) -
Heparanase Is a Putative Mediator of Endothelial Glycocalyx Damage in COVID-19 – A Proof-of-Concept Study
by: Carolin Christina Drost, et al.
Published: (2022-06-01) -
Investigating the Role of Heparanase in Breast Cancer Development Utilising the MMTV-PyMT Murine Model of Mammary Carcinoma
by: Krishnath M. Jayatilleke, et al.
Published: (2023-06-01) -
Elucidating the Consequences of Heparan Sulfate Binding by Heparanase 2
by: Miriam Gross-Cohen, et al.
Published: (2021-01-01)